Latest Breaking News On - Tumour institute - Page 1 : comparemela.com

Title: A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations. Lead Author Session: Abstract Number: About Savolitinib Savolitinib is an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase which has been shown to function abnormally in many types of solid tumors promoting tumor growth, angiogenesis, and metastasis. Savolitinib has been studied in over 1,100 patients to date. In clinical studies, it has shown promising clinical efficacy in patients with MET gene alterations in multiple tumor types with an acceptable safety profile.

Lin shenYanzhi cuiFilip jankuValld hebronYuxian baiCristina suXianjun yuArvind dasariScott paulsonBaylor sammons cancer centerVirtual scientific programUniversity cancer hospital instituteMd anderson cancer centerChina limitedFudan university shanghai cancer centerTumour institute